Clevidipine in Neurocritical Patients

Completed

• Conditions: High Blood Pressure

• Registration Number: NCT05168059
• Lead Sponsor: Hospital de Cruces

Brief Summary

Acute blood pressure elevation is a frequent problem in neurocritical patients. Its effective management is challenging and must avoid significant decreases of blood pressure leading to lower cerebral perfusion pressure worsening ischemia and elevations probably associated with bleeding, rebleeding or hematoma expansion associated with poor prognosis

Detailed Description

Retrospective, observational and single-group study for observe effectiveness and safety of clevidipine for perioperative control of hypertension in patients admitted to Post-Operative Intensive Care Unit after thrombectomy for stroke, intracerebral hemorrhage requiring surgical treatment, embolization of aneurysm after subarachnoid hemorrhage, scheduled neurosurgical and neuroradiology procedures.

Study Timeline

• Study Start: 2017-01-01
• Primary Completion: 2018-12-31
• Study Completion: 2019-09-01
• Study First Submitted: 2021-11-18
• Status Verified: 2021-12
• Study First Submitted QC: 2021-12-20
• Last Update Submitted: 2021-12-20
• Study First Posted: 2021-12-23
• Last Update Posted: 2021-12-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Not specified
• Target Recruitment: 33

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effectiveness of clevidipine	1 to 6 hour of clevidipine infusion beginning	Percentage of patients achieving target systolic blood pressure (SBP)

Secondary Outcome Measures

Name	Time	Method
Incidence of adverse events related to clevidipine treatment	1 hour after beginning to 24 hours after clevidipine infusion stop	Tachycardia, atrial fibrillation, hypotension, fever, acute kidney failure, nausea, headache and facial redness.

Trial Locations

Locations (1)

Biocruces; 🇪🇸 Barakaldo, Vizcaya, Spain